Evaluating Aprepitant single-dose plus granisetron and dexamethasone in children receiving highly emetogenic chemotherapy for the prevention of chemotherapy-induced nausea and vomiting: A triple-blinded randomized clinical trial

Evaluating Aprepitant single-dose plus granisetron and dexamethasone in children receiving highly emetogenic chemotherapy for the prevention of chemotherapy-induced nausea and vomiting: A triple-blinded randomized clinical trial

Blog Article

Introduction: This study was performed to evaluate the degree of 3-day Controller chemotherapy-induced nausea and vomiting (CINV) in children with cancer who received highly emetogenic chemotherapy (HEC) to ascertain the efficacy of aprepitant single-dose on dayL 1 plus granisetron and dexamethasone (DEX).Methods: This clinical trial study was conducted on 120 patients in the age range of 5 to 18 years old who received chemotherapy.Patients were divided into two groups; Group A received aprepitant at 125 mg/kg on day 1 orally, followed by 80 mg/kg daily on days 2 and 3 and Group B received a single dose of aprepitant 125 mg/kg on day 1 orally and placebo on days 2 and 3.

All groups received granisetron 3 mg/m2 on day 1 and DEX on days 1 to 3.The primary and secondary endpoints were to evaluate the proportion of patients with acute, delayed and overall CINV within each group.Results: There were no significant differences between the two groups for vomiting, nausea or the use of rescue therapy.

The number of patients without vomiting on day 1 was similar in both groups (96.5% vs.98.

3%, respectively; p = 0.848).Conclusion: According to the results of this study, a single dose of aprepitant 125 mg/kg was as effective as administering three doses of aprepitant on 3 days.

Therefore, the use of a single dose of aprepitant in combination with other standard treatment regimens to prevent CINV in children who received HEC was safe Beach Toy and efficacious and can be beneficial.